Genetic Epidemiology, Translational Neurogenomics, Psychiatric Genetics and Statistical Genetics Laboratories investigate the pattern of disease in families, particularly identical and non-identical twins, to assess the relative importance of genes and environment in a variety of important health problems.
QIMR Home Page
GenEpi Home Page
About GenEpi
Publications
Contacts
Research
Staff Index
Collaborators
Software Tools
Computing Resources
Studies
Search
GenEpi Intranet
PMID
33912086
TITLE
Comorbid Chronic Pain and Depression: Shared Risk Factors and Differential Antidepressant Effectiveness.
ABSTRACT
The bidirectional relationship between depression and chronic pain is well-recognized, but their clinical management remains challenging. Here we characterize the shared risk factors and outcomes for their comorbidity in the Australian Genetics of Depression cohort study ( = 13,839). Participants completed online questionnaires about chronic pain, psychiatric symptoms, comorbidities, treatment response and general health. Logistic regression models were used to examine the relationship between chronic pain and clinical and demographic factors. Cumulative linked logistic regressions assessed the effect of chronic pain on treatment response for 10 different antidepressants. Chronic pain was associated with an increased risk of depression (OR = 1.86 [1.37-2.54]), recent suicide attempt (OR = 1.88 [1.14-3.09]), higher use of tobacco (OR = 1.05 [1.02-1.09]) and misuse of painkillers (e.g., opioids; OR = 1.31 [1.06-1.62]). Participants with comorbid chronic pain and depression reported fewer functional benefits from antidepressant use and lower benefits from sertraline (OR = 0.75 [0.68-0.83]), escitalopram (OR = 0.75 [0.67-0.85]) and venlafaxine (OR = 0.78 [0.68-0.88]) when compared to participants without chronic pain. Furthermore, participants taking sertraline (OR = 0.45 [0.30-0.67]), escitalopram (OR = 0.45 [0.27-0.74]) and citalopram (OR = 0.32 [0.15-0.67]) specifically for chronic pain (among other indications) reported lower benefits compared to other participants taking these same medications but not for chronic pain. These findings reveal novel insights into the complex relationship between chronic pain and depression. Treatment response analyses indicate differential effectiveness between particular antidepressants and poorer functional outcomes for these comorbid conditions. Further examination is warranted in targeted interventional clinical trials, which also include neuroimaging genetics and pharmacogenomics protocols. This work will advance the delineation of disease risk indicators and novel aetiological pathways for therapeutic intervention in comorbid pain and depression as well as other psychiatric comorbidities.
Copyright © 2021 Roughan, Campos, García-Marín, Cuéllar-Partida, Lupton, Hickie, Medland, Wray, Byrne, Ngo, Martin and Rentería.
DATE PUBLISHED
2021
HISTORY
PUBSTATUS PUBSTATUSDATE
received 2020/12/18
accepted 2021/03/12
entrez 2021/04/29 06:25
pubmed 2021/04/30 06:00
medline 2021/04/30 06:01
AUTHORS
NAME COLLECTIVENAME LASTNAME FORENAME INITIALS AFFILIATION AFFILIATIONINFO
Roughan WH Roughan William H WH Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
Campos AI Campos Adrián I AI Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
García-Marín LM García-Marín Luis M LM Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
Cuéllar-Partida G Cuéllar-Partida Gabriel G UQ Diamantina Institute, The University of Queensland and Translational Research Institute, Brisbane, QLD, Australia.
Lupton MK Lupton Michelle K MK Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Hickie IB Hickie Ian B IB Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia.
Medland SE Medland Sarah E SE Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Wray NR Wray Naomi R NR Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.
Byrne EM Byrne Enda M EM Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.
Ngo TT Ngo Trung Thanh TT UQ Diamantina Institute, The University of Queensland and Translational Research Institute, Brisbane, QLD, Australia.
Martin NG Martin Nicholas G NG Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Rentería ME Rentería Miguel E ME Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
INVESTIGATORS
JOURNAL
VOLUME: 12
ISSUE:
TITLE: Frontiers in psychiatry
ISOABBREVIATION: Front Psychiatry
YEAR: 2021
MONTH:
DAY:
MEDLINEDATE:
SEASON:
CITEDMEDIUM: Print
ISSN: 1664-0640
ISSNTYPE: Print
MEDLINE JOURNAL
MEDLINETA: Front Psychiatry
COUNTRY: Switzerland
ISSNLINKING: 1664-0640
NLMUNIQUEID: 101545006
PUBLICATION TYPE
PUBLICATIONTYPE TEXT
Journal Article
COMMENTS AND CORRECTIONS
GRANTS
GENERAL NOTE
KEYWORDS
KEYWORD
antidepressant
chronic pain
comorbidity
depression
suicide
treatment response
MESH HEADINGS
SUPPLEMENTARY MESH
GENE SYMBOLS
CHEMICALS
OTHER ID's